Section 04
Market Analysis
$7.8T longevity economy — nobody owns the middle market
TL;DR
The longevity market will be worth $7.8 trillion by 2030. The biggest players either do testing OR treatment, but nobody does both affordably and remotely. Function Health ($2.5B valuation, 100K members) does blood tests but can't treat you. Lifeforce treats but barely tests. Fountain Life does both but is geographically limited to 4-6 US centers. BioForge owns the gap: real testing AND real treatment, fully remote, starting at $365 for blood work that funnels into $299-999/month peptide subscriptions. Adults 30-55 who are serious about health optimization — both men and women — are the highest-value customer base. Pre-filled pens are the differentiator nobody else has.
Total Addressable Market
$150-300K
SOM
$7.8T
TAM
$15.8B
SAM
Total Addressable
Global longevity economy by 2030 — encompassing diagnostics, therapeutics, digital health, supplements, and wellness
Serviceable Available
US + UAE + EU adult longevity market: DTC/telehealth diagnostics + peptide therapy + AI health platforms for health-conscious adults 30-55
Serviceable Obtainable
Year 1 target — conservative with $5-10K/month marketing spend, ~14-28 new customers/month at $350 CAC
Market Segments
Blood Work & Diagnostics (Funnel)
$365 one-time blood work + first consultation + protocol recommendation. Gateway product that IS the solution, not just the problem. Cost $100-180 to BioForge. Function Health proved the model at $2.5B valuation with 100K members.
Recovery & Healing Peptides
BPC-157, TB-500 — #1 demand from people who train hard. Tendon, joint, muscle recovery. Pre-filled pens as differentiator. Wholesale: $18-36 per vial. Retail: $299-699/month.
Performance & Body Composition
CJC-1295+Ipamorelin (GH optimization), semaglutide (body recomp), Epitalon (longevity). Core of the peptide subscription revenue. Wholesale $16-27, retail $299-699/month.
Longevity & Anti-Aging
NAD+ ($36 wholesale), GHK-Cu ($22.50 wholesale), Thymosin Alpha-1 ($24 wholesale), comprehensive longevity protocols. Growing fastest among high-income adults. Premium tier ($799-999/month).
Pre-Filled Pen Premium
First mover advantage. Zepbound pen = $1,086 vs vial = $349-499 (2-3x premium). NOBODY offers pens for BPC-157, TB-500, CJC-1295/Ipamorelin. This segment justifies the Longevity tier pricing.
Competitive Landscape
| Company | Revenue | Employees | Model | Margin | Peptides |
|---|---|---|---|---|---|
| Function Health ↗ | $2.5B valuation, 100K members | 100+ | Blood testing platform, 160+ biomarkers, $365/yr (first year), $499/yr after. 500K waitlist before launch. | Est. 45-60% gross (thin due to lab costs flowing to Quest/LabCorp) | ✗ |
| Lifeforce ↗ | Est. $50-100M | 200+ | Tony Robbins + Amazon partnership, $149/mo ongoing after $549 initial diagnostics, treatment + coaching | Est. 50-60% gross | ✓ |
| Fountain Life ↗ | Est. $50-100M | 300+ | Luxury longevity clinics, $6.5-21.5K/yr, full diagnostics + treatment including MRI, cardiac screening | Est. 40-50% gross | ✓ |
| Prenuvo ↗ | $100M+ revenue, profitable | 300+ | Full-body MRI scans, $999-2,499 per scan, growing clinic network | Est. 40-50% gross | ✗ |
| 10X Health (Grant Cardone / Gary Brecka) ↗ | Est. $50-100M | 100+ | Franchise model, gene testing + supplements, $500-5K per engagement. Brecka lawsuit ongoing. | Est. 60-70% gross | ✗ |
| Hone Health ↗ | Est. $30-50M | 100+ | Men's health telehealth, $65 entry, $25-149/mo membership, hormone optimization | Est. 50-60% gross | ✗ |
| AgelessRx ↗ | Est. $10-20M | Est. 20-30 | Cheapest peptide prescriptions online, $25-199/mo, no blood work, minimal consult | Est. 40-50% gross | ✓ |
| Marek Health (MPMD Community) ↗ | Est. $20-40M | Est. 30-50 | Comprehensive health, $300-600/mo, blood work ($250-2,000/panel) + treatment, Derek (MPMD) community | Est. 50-60% gross | ✓ |
| Peak Health ↗ | Est. $10-30M | Est. 20-50 | Telehealth concierge, $599/mo including labs + physician + treatments | Est. 55-65% gross | ✓ |
| Wild Health ↗ | Est. $20-40M | Est. 50-100 | Genomics-based precision medicine, $199-2,083/mo ($362-25,000/yr), genetic analysis + labs + physician | Est. 50-60% gross | ✓ |
| Hims & Hers ↗ | $2.4B (2025) | 2,442 | Full-stack telehealth, own prescribers, $149/mo membership. Started men-only, added Hers, reached $2.4B. | 5.5% net | ✓ |
| Medvi ↗ | $401M (2025), $1.8B annualized run rate | 2 | Thin-layer telehealth via CareValidate/OpenLoop. GLP-1 focused. | 16.2% net (claimed) | ✗ |
| BioForge (Target) | $80-150M (Y5) | 8-12 | Thin-layer, multi-market | 22% net (target) | ✓ |
The longevity market has a massive gap. Function Health proved testing demand at $2.5B valuation but can't treat. Lifeforce/Marek treat but have weak diagnostics. Fountain Life does both but is GEOGRAPHICALLY LIMITED to 4-6 US centers (not "too expensive" — we have similar price tiers in our roadmap). Nobody combines comprehensive testing AND treatment, fully remote, with pre-filled pens as a differentiator. BioForge fills this exact gap: blood work at $365 as the funnel (includes first consultation and protocol recommendation), then $299-999/month peptide subscriptions, fully remote via 2,000+ Quest labs and peptides shipped home. Demand is latent, not aware — education-first content strategy ("Why do you feel tired at 40?") creates the market.